News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
689,399 Results
Type
Article (39203)
Company Profile (282)
Press Release (649914)
Section
Business (203931)
Career Advice (1999)
Deals (35383)
Drug Delivery (89)
Drug Development (80872)
Employer Resources (168)
FDA (16108)
Job Trends (14814)
News (344698)
Policy (32452)
Tag
Academia (2530)
Alliances (49241)
Alzheimer's disease (1281)
Approvals (16070)
Artificial intelligence (158)
Bankruptcy (354)
Best Places to Work (11595)
Biotechnology (199)
Breast cancer (201)
Cancer (1477)
Cardiovascular disease (119)
Career advice (1665)
Cell therapy (305)
Clinical research (64882)
Collaboration (543)
Compensation (301)
COVID-19 (2546)
C-suite (127)
Data (1451)
Diabetes (184)
Diagnostics (6187)
Earnings (84998)
Employer resources (146)
Events (110307)
Executive appointments (455)
FDA (16856)
Funding (494)
Gene therapy (212)
GLP-1 (613)
Government (4335)
Healthcare (18735)
Infectious disease (2642)
Inflammatory bowel disease (112)
Interviews (309)
IPO (16375)
Job creations (3625)
Job search strategy (1418)
Layoffs (424)
Legal (7866)
Lung cancer (220)
Manufacturing (212)
Medical device (13225)
Medtech (13230)
Mergers & acquisitions (19243)
Metabolic disorders (485)
Neuroscience (1632)
NextGen: Class of 2025 (6504)
Non-profit (4471)
Northern California (1840)
Obesity (276)
Opinion (185)
Parkinson's disease (105)
Patents (128)
People (56589)
Phase I (20189)
Phase II (28576)
Phase III (21292)
Pipeline (602)
Postmarket research (2561)
Preclinical (8551)
Radiopharmaceuticals (238)
Rare diseases (279)
Real estate (5893)
Regulatory (21755)
Research institute (2312)
Resumes & cover letters (349)
Southern California (1581)
Startups (3565)
United States (16293)
Vaccines (571)
Weight loss (191)
Date
Today (193)
Last 7 days (893)
Last 30 days (2086)
Last 365 days (34988)
2025 (1255)
2024 (35251)
2023 (40077)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (202)
Asia (37359)
Australia (6099)
California (4153)
Canada (1525)
China (350)
Colorado (188)
Connecticut (198)
Europe (80019)
Florida (584)
Georgia (141)
Illinois (408)
Indiana (235)
Maryland (671)
Massachusetts (3217)
Michigan (180)
Minnesota (311)
New Jersey (1166)
New York (1177)
North Carolina (773)
Northern California (1840)
Ohio (150)
Pennsylvania (983)
South America (1093)
Southern California (1581)
Texas (596)
Utah (118)
Washington State (424)
689,399 Results for "immunovaccine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) is pleased to announce has completed the acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets of former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA (“IMV”).
February 21, 2024
·
3 min read
Deals
BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.
BioVaxys Technology Corp. announced that it has executed the definitive Asset Purchase Agreement dated February 11th, 2024 to acquire the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA.
February 12, 2024
·
10 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
Hologic Completes Acquisition of Gynesonics, Inc.
January 7, 2025
·
4 min read
Press Releases
GSK Enters Agreement to Acquire IDRx, Inc.
January 13, 2025
·
8 min read
Press Releases
LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy
January 6, 2025
·
3 min read
Press Releases
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
·
2 min read
Press Releases
111, Inc. Announces ADS Ratio Change
January 8, 2025
·
4 min read
Press Releases
genXtraits Inc. and Solis Agrosciences enter collaboration agreement
January 13, 2025
·
3 min read
Press Releases
Agendia, Inc. Provides Review of Successful 2024
January 9, 2025
·
7 min read
1 of 68,940
Next
